Novartis Licenses Novel Drug for Hepatitis C Infection
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 71 (Table of Contents)
Published: 6 May-2006
DOI: 10.3833/pdr.v2006.i71.520 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
The youthful antiviral drug discovery company Idenix Pharmaceuticals has licensed its Phase II compound valopicitabine for the treatment of hepatitis C to Novartis in a potential deal value of over US$0...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS